Genotypic and phenotypic features of MRSA with an incomplete hemolysis phenotype in a tertiary teaching hospital in China Authors: Wanjun Chen, Roushan Liu, Minghui Hao, Yingjun Wang, Wenqi Zheng, Junrui Wang Published: 2026 ABSTRACT AbstractBackgroundMethicillin-resistant Staphylococcus aureus (MRSA) is a common bacterial pathogen responsible for hospital- and community-acquired infections and typically exhibits a β-hemolytic phenotype. Notably, MRSA with an incomplete hemolytic phenotype (SIHP-MRSA) has been reported in few studies and has been shown to display altered virulence and resistance to last-resort antibiotics. However, the detailed genotypic and phenotypic characteristics of SIHP-MRSA clinical isolates remain unclear. This study aims to analyze the genotypic and phenotypic characteristics of SIHP-MRSA clinical isolates using a large sample size and to explore potential molecular mechanisms underlying the incomplete hemolytic phenotype, altered biofilm production capability, and elevated antimicrobial resistance of SIHP-MRSA.MethodsMRSA clinical isolates were obtained from patients admitted to the Affiliated Hospital of Inner Mongolia Medical University during 2010–2024, and hemolytic patterns were visually assessed on blood agar plates. Multilocus sequence typing (MLST), staphylococcal protein A (spa) typing, and staphylococcal cassette chromosome mec (SCCmec) typing were used to characterize the molecular genotypes of SIHP-MRSA isolates, whereas PCR was used to identify the distribution of virulence genes. Mutations in the agrA gene among SIHP-MRSA isolates were identified via Sanger sequencing. Biofilm formation capabilities were assessed using Congo red agar and crystal violet staining, while antimicrobial resistance profiles were determined using the VITEK-2 Compact system and the broth microdilution method.ResultsAmong 1,122 MRSA clinical isolates analyzed in this study, 28.5% (320/1,122) were classified as SIHP-MRSA. The majority of isolates were isolated from lower respiratory tract samples (61.8%), followed by whole blood (9.0%) and secretions (8.5%). Molecular typing results indicated that ST5-t2460-II (85.6%, 274/320) and ST59-t437-IVa (10.3%, 33/320) were the dominant clones. Among these isolates, 21.5% (69/320) carried the pvl gene and 56.8% (182/320) carried tsst-1. Notably, 35 isolates carried both pvl and tsst-1 genes, primarily belonging to ST5-t2460-II (93.5%, 29/31). Overall, 13.4% (43/320), 45.9% (147/320), and 40.6% (130/320) of SIHP-MRSA isolates were classified as weak, moderate, and strong biofilm producers, respectively. The agrA-I238K mutation occurred in 89.7% (287/320) of isolates, and 57.1% (164/287) and 61.3% (176/287) of isolates exhibited reduced susceptibility to teicoplanin and daptomycin, respectively. Elevated teicoplanin MICs (≥ 2 µg/mL) and daptomycin MICs (≥ 1 µg/mL) were significantly more frequent in SIHP-MRSA isolates with the agrA-I238K mutation than in isolates with a complete hemolytic phenotype (SCHP-MSRA) (P = 0.007).ConclusionsThis study is the first to report a high prevalence of SIHP-MRSA in a tertiary teaching hospital in China and to describe its genotypic diversity. These isolates showed enhanced biofilm formation, reduced susceptibility to daptomycin and teicoplanin, strong nosocomial transmission potential, and higher carriage rates of pvl and tsst-1 virulence genes. The significant genotypic and phenotypic features of SIHP-MRSA identified in this study highlight the previously neglected clinical significance of this MRSA subtype and emphasize the need for further exploration into its pathogenicity among vulnerable populations and its underlying molecular mechanisms.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12866-026-05352-6.Keywords: Staphylococcus aureus, Methicillin resistance, Incomplete hemolysis, Molecular characterization, Biofilm formation Background Methicillin-resistant Staphylococcus aureus (MRSA) remains a major cause of hospital- and community-acquired infections, with evolving genetic and phenotypic traits complicating clinical management [1]. Staphylococcus aureus displays pathogenicity largely through diverse virulence factors, including Panton–Valentine leucocidin (pvl) and toxic shock syndrome toxin-1 (tsst-1), clones of which are strongly associated with high virulence and severe disease [2–4]. Another important group of toxins, hemolysins, consists of α-, β-, γ-, and δ-hemolysins, whose expression is regulated via the Agr-QS system [4]. Through these toxins, S. aureus typically exhibits a complete or transparent hemolytic phenotype on blood agar plates. However, a novel hemolytic pattern, termed MRSA with an incomplete hemolytic phenotype (SIHP-MRSA), has emerged [5]. SIHP-MRSA features an opaque, darker hemolytic ring that contrasts with the transparent ring observed in isolates displaying the MRSA with complete hemolytic phenotype (SCHP-MRSA). However, only a few preliminary descriptions have focused on its phenotypic and genotypic characteristics, and substantial knowledge gaps regarding SIHP-MRSA persist. Zhan et al. [5] reported that SIHP-MRSA isolates carried the tsst-1 gene at a high frequency and stimulated macrophages to secrete greater levels of proinflammatory cytokines (such as IL-2, IL-6, and IL-17 A), suggesting enhanced virulence of SIHP-MRSA isolates. Gao et al. [6] confirmed that the carriage rate of the pvl gene among SIHP-MRSA isolates reached 53.33%, markedly exceeding that observed in SCHP-MRSA isolates. Moreover, MRSA isolates with this phenotype exhibit altered virulence traits, including decreased hemolytic activity, reduced intracellular survival, modified biofilm formation, and distinct antimicrobial resistance patterns. These features have been closely correlated with the agrA-I238K mutation [7]. The potential importance of SIHP-MRSA appears underestimated in the existing literature, and several key issues regarding this MRSA subtype remain underexplored. First, currently available studies on SIHP-MRSA generally involve limited isolate numbers, and no report has detailed the molecular epidemiological and pathogenic characteristics of SIHP-MRSA clinical isolates based on a large sample size. Second, the epidemiological features of SIHP-MRSA clinical isolates have not been adequately clarified, including the characteristics of high-risk populations infected with SIHP-MRSA. Moreover, although some studies have implied elevated pathogenic potential and altered antimicrobial resistance profiles, the capacity for nosocomial transmission and persistence of SIHP-MRSA among susceptible patients is poorly characterized. Third, several pathogenic features of SIHP-MRSA have been partially described, including its distinctive virulence gene repertoire, enhanced biofilm-forming ability, and unique antimicrobial resistance profile. However, the clinical relevance and regulatory mechanisms underlying these features remain unclear. Finally, whether the agrA-I238K mutation represents the sole molecular marker and driving mechanism of SIHP-MRSA is still uncertain, and other potential contributors have not been explored. Addressing these knowledge gaps will facilitate a deeper understanding of its pathogenic and evolutionary mechanisms. In this study, a retrospective investigation with a large sample size and extended study period was conducted at a tertiary teaching hospital in China to further analyze the phenotypic and genotypic characteristics of SIHP-MRSA clinical isolates, their underlying molecular mechanisms, and the epidemiological features of patients infected with SIHP-MRSA. Methods Identification of SIHP-MRSA From January 2010 to December 2024, 1,122 MRSA isolates were identified from various specimens obtained from patients admitted to the Affiliated Hospital of Inner Mongolia Medical University, China. The isolates were stored at − 80 °C until testing. For this study, isolates were inoculated onto sheep blood agar plates (Tianjin Jinzhang, China) and incubated at 35 °C in 5% CO₂ for 24 h. Species identification was confirmed using MALDI-TOF MS (EXS3000, Zybio, China). Hemolytic patterns on blood agar were visually examined, and SIHP isolates were compared with reference strains ATCC 43,300, ATCC 29,213, and ATCC 25,923. To evaluate SIHP phenotype stability, 10 sequential subcultures were performed by transferring representative colonies onto fresh sheep blood agar plates every 24 h [5]. Patients’ clinical epidemiological data were collected and analyzed retrospectively. Molecular typing Validated SIHP-MRSA isolates were plated on Columbia blood agar and incubated at 37 °C for 24 h. Single colonies were selected for genomic DNA extraction using commercial kits (TianGen, Beijing, China). Multilocus sequence typing (MLST) was performed following the procedure of Enright et al. [8]. Briefly, seven housekeeping genes (arcC, aroE, glpF, gmk, pta, tpi, and yqiL) were amplified via PCR, and products were purified and sequenced using Sanger sequencing. The resulting sequences were submitted to the PubMLST database (https://pubmlst.org/organisms/staphylococcus-aureus) for automated allele number assignment and sequence type (ST) determination. Spa typing was performed following Ravaioli et al. [9]. Using extracted DNA as the template, PCR amplification targeted the polymorphic X region (short sequence repeat region) of the spa gene. Resulting sequences were aligned using the Ridom SpaServer database (http://www.spaserver.ridom.de) for spa type confirmation [9, 10]. Staphylococcal cassette chromosome mec (SCCmec) typing was conducted using the protocol outlined by Zhang et al. [11], employing multiplex PCR. SCCmec types I–V were determined based on combinations of cassette chromosome recombinase types and mec class patterns. Sequence analysis of agrA Total DNA from the tested isolates was extracted as described above and used as the template for PCR amplification of agrA, with primers designed based on reference N315 (GenBank accession no. NC_002745.2): agrA F (GTCTTATTAGATACAATTATCG) and agrA R (CAGCTATACAGTGCATTTGCTAG). PCR products were examined via agarose gel electrophoresis, purified using the TIANGEN Gel Extraction Kit (TIANGEN Inc., Beijing, China), and sequenced on an ABI 3730xl sequencer (Thermo Fisher Scientific, Waltham, MA, USA). Sequence analysis was performed using DNAMAN software [7]. Detection of virulence genes DNA extraction for SIHP-MRSA isolates was performed as described for molecular typing. PCR assays were used to screen for 24 virulence genes, including hla, β-hemolysin (hlb), hlc, δ-hemolysin (hld), hlga, hlgb, hlgc, pvl, tsst-1, lukM, lukDE, sea, seb, sec, sed, and see, using primers listed in (Table 1). PCR was conducted on an A300 gradient instrument (Hangzhou Longji Scientific Instrument Co., Ltd., China), with reaction conditions based on published protocols [12–14]. Table 1Primers used in this studyVirlence geneOligonucleotide sequence (5’-3’)Amplicon size (bp)Reference hla-F ATGAAAACACGTATAGTCAGCTCAGTAACAAC960[12] hla-R TTAATTTGTCATTTCTTCTTTTTCCCAATCGA hlb-F AAATTAGAGCTGAACAAATGAAAGAAATCAG825[12] hlb-R TTTCGCAATTGAATTTGATTGAGGGTCCC hld-F ATGGCACAAGATATCATTTCAACAATCAGTG81[12] hld-R TTATTTTTTAGTGAATTTGTTCACTGTGTCG hlgA-F ATGATTAAAAATAAAATATTAACAGCAACTTTAGCAGTT860[12] hlgA-R TTACTTAGGTGTGATGCTTTTAATTTTTACTTCATGTG hlgB-F ATGAAAATGAATAAATTAGTCAAATCATCCGTTGC792[12] hlgB-R TTACTGTAATTTTAGATTTTTTAGCGCCATCTTG hlgC-F GCTTAAAAATAAAATATTAACTACAACTTTATCTGTGAGC720[12] hlgC-R TCAATTCTGTCCTTTCACCTTGATTTCATGAG pvl-F ATCATTAGGTAAAATGTCTGGACATGATCCA433[13] pvl-R GCATCAASTGTATTGGATAGCAAAAGC tsst-1-F GCTTGCGACAACTGCTACAG559[14] tsst-1-R TGGATCCGTCATTCATTGTTAT lukE-D-F TGAAAAAGGTTCAAAGTTGATACGAG269[14] lukE-D-R TGTATTCGATAGCAAAAGCAGTGCA lukM-F TGGATGTTACCTATGCAACCTAC780[14] lukM-R GTTCGTTTCCATATAATGAATCACTAC sea-F GCAGGGAACAGTTTAGGC520[14] sea-R GTTCTGTAGAAGTATGAAACACG seb-F ACATGTAATTTTGATATTCGCACTG667[14] seb-R TGCAGGCATCATGTCATACCA sec-R CTTGTATGTATGGAGGAATAACAA283[14] sec-F TGCAGGCATCATATCATACCA sed-F CTAGTTTGGTAATATCTCCT317[14] sed-R TAATGCTATATCTTATAGGG see-F TACCAATTAACTTGTGGATAGAC170[14] see-R CTCTTTGCACCTTACCGC Primers used in this study Biofilm formation assay The Congo red agar (CRA) method was used to quantitatively assess biofilm formation in SIHP-MRSA isolates. Fresh colonies were inoculated onto blood agar supplemented with 0.8 g/L Congo red and 5% sucrose (Solarbio, Beijing, China). Plates were incubated at 37 °C for 24 h and then left at room temperature for an additional 24 h. Black colonies or black colonies with a reddish tint were considered biofilm producers, whereas fully red colonies were categorized as nonproducers [12]. Biofilm-positive isolates identified via the CRA method were further evaluated using the crystal violet staining method as described previously [13, 14]. Fresh colonies from blood agar plates were collected and suspended to a final concentration equivalent to a 0.5 McFarland standard, and subsequently diluted 1:100 into a 96-well flat-bottom microplate, with three biological replicates prepared for each isolate. The microplate was incubated without agitation at 37 °C for 24 h to allow mature biofilm formation. After removing the culture supernatant, wells were washed twice with PBS and air-dried. Each well received 200 µL of 2.5% methanol for 15 min at room temperature, followed by staining with 200 µL of 0.2% crystal violet solution for 20 min. Wells were again washed twice with PBS, followed by treatment with 150 µL of acetic acid. The absorbance (OD) of the destained solution was determined at 620 nm on a Sunrise microplate reader (Tecan, Switzerland). All assays were performed in triplicate, with uninoculated tryptic soy broth serving as the negative control. The cutoff optical density (ODc) was defined as the mean OD value of negative control wells plus 3 × standard deviations. Biofilm-producing capacity was classified according to OD values: OD > 4 × ODc indicated strong biofilm production, 2 × ODc ≤ OD ≤ 4 × ODc moderate biofilm production, OD ≤ 2 × ODc weak biofilm production, and OD ≤ ODc no biofilm production [15, 16]. Antimicrobial susceptibility test Antimicrobial susceptibility was assessed using the VITEK® AST-GP67 card (bioMérieux Clinical Diagnostics, France) on the VITEK-2 Compact automated susceptibility testing system (BioMérieux, France), examining 14 antimicrobials: penicillin, oxacillin, gentamicin, rifampicin, ciprofloxacin, levofloxacin, moxifloxacin, clindamycin, erythromycin, linezolid, vancomycin, quinupristin/dalfopristin, tetracycline, and tigecycline. Susceptibility to daptomycin (0.125, 0.250, 0.500, and 1.000 µg/mL) and teicoplanin (1, 2, 4, and 8 µg/mL) was determined via microdilution. Following the instructions for the VITEK 2 AST-GP67 Test Kit (bioMérieux, Durham, NC, USA) and the quality control requirements for MIC determination outlined by the Clinical and Laboratory Standards Institute guidelines (CLSI M100, 35th edition [17]. S. aureus ATCC 29213 was selected as the quality control strain for antimicrobial susceptibility testing in this study. Results were interpreted according to the Clinical and Laboratory Standards Institute guidelines (CLSI M100, 35th edition). Statistical analysis Statistical analysis was performed using SPSS 27.0. One-way ANOVA or nonparametric tests were applied for multiple-group comparisons, whereas independent-samples t-tests were used for between-group comparisons. Statistical significance was defined as P < 0.05. Results Identification of SIHP-MRSA Among the 1,122 MRSA clinical isolates analyzed, 320 isolates displayed the SIHP phenotype. As shown in Fig. 1, control MRSA isolates produced characteristic transparent β-hemolytic rings surrounding colonies after 24 h of incubation on blood agar. Clinical SIHP-MRSA isolates exhibited two hemolytic patterns: a prominent dark, opaque incomplete ring around colonies in 95.6% of isolates (306/320) and a linear enhanced zone around colonies in 4.4% (14/320). Hemolytic characteristics of incomplete hemolysis MRSA a-b SIHP, c-d Typical hemolysis of clinical isolates, e-f Linear hemolysis, g-i ATCC43300, ATCC29213 and ATCC25923 Clinical epidemiological features The clinical distribution of the 320 SIHP-MRSA isolates is shown in (Fig. 2). Most isolates originated from male patients (68.4%, 219/320), and 24.1% (77/320) were collected from the department of neurosurgery. Sputum was the most common specimen source (61.9%), followed by whole blood (9.7%), bronchoalveolar lavage fluid (9.1%), and wound secretion (8.5%). Additionally, 86.6% of isolates were recovered between 2018 and 2024. Epidemiological characteristics of 320 SIHP-MRSA isolates. ANeurosurgery (NS), Rehabilitation and Vocational Ward (RVW), Orthopedics (ORT), Department of Neurology (DN), Department of Respiratory Medicine (DRM), Neurosurgical Intensive Care Unit (NICU), Emergency Department (ED). BSputum (SP), Whole Blood (WB), Bronchalveolar Lavage Fluid (BALF), Wound Secretion (SE), Throat Swab (TS). CFemale (F), Male (M) Genotypic characteristics of SIHP-MRSA As summarized in Table 2, the 320 SIHP-MRSA isolates were classified into five STs, six spa types, and four SCCmec types. ST5 was the dominant clone (85.6%, 274/320), followed by ST59 (10.3%, 33/320), ST239 (3.4%, 11/320), ST39 (0.3%, 1/320), and ST22 (0.3%, 1/320). Regarding spa types, t2460 was most prevalent (85.6%, 274/320), followed by t437 (10.3%, 33/320), t037 (2.2%, 7/320), t030 (1.2%, 4/320), and t034 (0.31%, 1/320). For SCCmec typing, type II was the predominant genotype (85.6%, 274/320), followed by IVa (8.8%, 28/320), V (1.9%, 6/320), and III (3.4%, 11/320). Combining typing data, ST5-II-t2460 and ST59-IVa-t437 were the leading clones, constituting 85.6% (274/320) and 8.8% (28/320) of isolates, respectively. Table 2Molecular characteristics of 320 SIHP-MRSA isolatesMLST type(n)Spa type(n)SCCmec type (n)ST5 (274)t2460 (274)Ⅱ (274)ST59 (33)t437 (33)Ⅳa (28)Ⅴ (5)ST239 (11)t037 (7)Ⅲ (7)t030 (4)Ⅲ (4)ST39 (1)t034 (1)Ⅱ (1)ST22 (1)t2460 (1)Ⅴ (1)n denotes the number of isolates belonged to each type Molecular characteristics of 320 SIHP-MRSA isolates n denotes the number of isolates belonged to each type Sequence analysis of agrA mutations Sanger sequencing revealed a single missense substitution in agrA, namely T3124A (I238K), present in 89.7% (290/320) of SIHP isolates. These agrA-I238K mutant isolates predominantly belonged to ST5 (91.6%) and ST59 (5.9%) types. Distribution of virulence genes As shown in Table 3, the 320 SIHP-MRSA isolates displayed diverse virulence gene profiles. Hemolysin genes were almost universally present: all isolates carried hlb, hld, and γ-hemolysin (hlg-ABC), whereas hla carriage was slightly lower at 96.8% (284/320). In SIHP-MRSA, staphylococcal enterotoxin gene abundance varied, including sea (52.5%), seb (70.9%), Sect. (90.6%), sed (3.4%), and see (2.5%). Among leukotoxin genes, lukDE was frequently detected (93.4%), whereas lukM was uncommon (7.5%). Notably, tsst-1 and pvl were identified in 56.8% and 21.5% (69/320) of isolates, respectively. Virulence gene frequencies differed markedly among isolates across genotypes (Table 3). Compared with ST59-t437-IV/V, ST5-t2460-II isolates carried significantly higher rates of tsst-1, sea, seb, and sec but lower rates of lukM and sed. The ST5-t2460-II clone showed a high prevalence of tsst-1 (59.4%), whereas pvl was more frequent among ST59-t437-IVa isolates (26.4%). Regarding the distribution of pvl/tsst-1 double-positive (PT) isolates, 12% belonged to ST5-t2460-II and 3.1% to ST59-t439-IV (Table 3). Full virulence gene expression profiles for each strain are provided in Appendix 1. Table 3Comparison of positive rates of virulence genes among MRSA isolates belonged to ST5-t2460-II and ST59-t437-IVa/Ⅴ clonesVirulence genesTotal(n = 320)ST5-t2460-II(n = 274)ST59-t437-IVa/Ⅴ(n = 33)P values pvl 21.5%22.2%26.4%0.667 tsst-1 56.8%59.4%39.3%0.044 pvl+tsst-1 10.9%12.0%3.1%0.005 hla 96.8%97.1%100%0.398 hlb 100%100%100%> 0.999 hld 100%100%100%> 0.999 hlg-ABC 100%100%100%> 0.999 sea 52.5%54.7%30.3%0.014 seb 70.9%75.5%39.3%< 0.001 sec 90.6%92.3%78.7%0.023 sed 3.4%3.2%6%0.750 see 2.5%2.5%3%0.677 lukDE 93.4%93.4%93.9%> 0.999 lukM 7.5%5.8%18.1%< 0.024 Comparison of positive rates of virulence genes among MRSA isolates belonged to ST5-t2460-II and ST59-t437-IVa/Ⅴ clones Prevalence of the predominant ST5-t2460-Ⅱ clone As shown in Fig. 3, ST5-t2460-Ⅱ isolates exhibited marked temporal and spatial clustering. Transmission was concentrated among patients in the departments of neurosurgery and rehabilitation medicine. Between May 2020 to December 2021, 32 isolates of this clone were persistently detected in patients from the department of neurosurgery, coinciding with five suspected nosocomial outbreaks. Four additional suspected outbreaks occurred from March to June 2023. Among 147 outbreak-associated isolates identified between 2018 and 2024, 16.3% (24/147) were PT isolates Distribution of ST5-t2460-Ⅱ SIHP-MRSA isolates during January 2018 to December 2024. Note: The line chart depicts the epidemiological characteristics of the PT (pvl/tsst-1 double-positive) isolates from 2018 to 2024 Biofilm formation capabilities of SIHP-MRSA Through CRA testing, 99.1% (317/320) of SIHP-MRSA isolates were classified as biofilm producers, whereas 1.0% (3/320) were considered nonproducers. Using crystal violet staining, 40.6%, 45.9%, and 13.5% of isolates were classified as strong, moderate, and weak biofilm producers, respectively. Three isolates (776, 828, and 54) were identified as weak producers based on crystal violet staining but nonproducers according to CRA testing. Figure 4 compares SIHP-MRSA (320) and SCHP-MRSA (802) isolates: 86.5% (277/320) of SIHP-MRSA isolates were moderate or strong biofilm producers, whereas 80.3% of SCHP-MRSA (644/802) isolates were weak or moderate producers. Among SIHP-MRSA isolates, pvl carriage rates were 32.4% (21/65), 35.8% (23/65), and 31.8% (21/65) in strong, moderate, and weak producers, respectively, whereas tsst-1 positivity was 35.2% (55/156), 34.6% (54/156), and 30.2% (47/156), respectively. Among PT isolates, 45.1% (14/31), 32.3% (10/31), and 22.6% (7/31) were classified as strong, medium, and weak biofilm producers, respectively. Biofilm characteritics of SIHP and SCHP isolates Phenotypic resistance profiles of SIHP-MRSA SIHP-MRSA isolates exhibited high rates of resistance to erythromycin (98.1%, 214/320), tetracycline (87.5%, 254/320), ciprofloxacin (89.1%, 285/320), levofloxacin (82.1%, 263/320), and moxifloxacin (82.5%, 264/320), whereas 53.1% (170/320) were resistant to gentamicin. Conversely, resistance to rifampicin, clindamycin, quinupristin/dalfopristin, and tigecycline was comparatively low (Table 4). All SIHP-MRSA isolates remained sensitive to linezolid and vancomycin. Compared with ST59-t437-IVa isolates, ST5-t2460-II isolates showed significantly higher rates of resistance to tetracycline (99.6% vs. 66.7%, P < 0.001) and fluoroquinolones (ciprofloxacin, 95.2% vs. 45.5%, P < 0.001; levofloxacin, 89.4% vs. 24.2%, P < 0.001; and moxifloxacin, 91.2% vs. 21.2%, P < 0.001). Table 4Antimicrobial resistance characteristics of SIHP-MRSA isolates belonging to different genotypesAntimicrobialsTotal(n = 320, % R)ST5-t2460-Ⅱ(n = 274, % R)ST59-t437-Ⅳa/Ⅴ(n = 33, % R)P valuesGentamicin53.1% (170/320)56.9% (156/274)15.2% (5/33)< 0.001Rifampicin9.1% (29/320)5.8% (16/274)9.1% (3/33)0.452Oxacillin100% (320/320)100% (274/274)100% (33/33)> 0.999Ciprofloxacin89.1% (285/320)95.2% (261/274)45.5% (15/33)< 0.001Levofloxacin82.1% (263/320)89.4% (245/274)24.2% (8/33)< 0.001Moxifloxacin82.5% (264/320)91.2% (250/274)21.2% (7/33)< 0.001Clindamycin98.1% (214/320)98.5% (270/274)93.9% (31/33)0.128Erythromycin98.1% (214/320)98.9% (271/274)90.9% (30/33)0.024Linezolid0% (0/320)0% (0/274)0% (0/33)> 0.999Vancomycin0% (0/320)0% (0/274)0% (0/33)> 0.999Teicoplanin0% (0/320)0% (0/274)0% (0/33)> 0.999Daptomycin0% (0/320)0% (0/274)0% (0/33)> 0.999Quinupristin/Dalfopr0.63% (2/320)0.7% (2/274)0% (0/33)0.645Tetracycline87.5% (254/320)99.6% (273/274)66.7% (22/33)< 0.001Tigecycline3.1% (10/320)3.6% (10/274)0% (0/33)0.347% R, Antimicrobial Resistance Rate Antimicrobial resistance characteristics of SIHP-MRSA isolates belonging to different genotypes % R, Antimicrobial Resistance Rate As shown in Fig. 5, SIHP-MRSA isolates had markedly higher MICs for teicoplanin and daptomycin compared with SCHP-MRSA isolates, indicating reduced susceptibility to these antibiotics. Specifically, reduced susceptibility occurred in 54.7% (175/320) and 61.2% (196/320) of SIHP isolates for teicoplanin (MIC ≥ 2 µg/mL) and daptomycin (MIC ≥ 1 µg/mL) compared with only 4.8% (38/802) and 3.8% (31/802) among SCHP-MRSA isolates, respectively. Distribution of teicoplanin and daptomycin MICs among SIHP-MRSA and SCHP-MRSA isolates Discussion Globally, MRSA infections are strongly associated with high morbidity and mortality among inpatients and continue to impose substantial burdens on healthcare systems [18], particularly with predominant clones, such as ST59, ST5, and ST239 [19–21].n this study, we examined a distinct MRSA subpopulation, namely SIHP-MRSA, which presents a nonclassical hemolytic phenotype and has been reported to exhibit potentially hypervirulent characteristics [4]. However, the prevalence and potential clinical significance of SIHP-MRSA remain underreported. During our investigation, we identified a high rate of SIHP-MRSA in a tertiary teaching hospital in China during 2016–2024. From an epidemiological perspective, SIHP-MRSA displayed clear temporal clustering from 2018 to 2024 and was primarily isolated from lower respiratory tract specimens and male patients. Additionally, several suspected nosocomial outbreaks occurred in the neurosurgery and rehabilitation departments, suggesting notable hospital-associated transmission potential. Therefore, the risks of nosocomial spread and outbreaks caused by SIHP-MRSA may have been previously underestimated, particularly among vulnerable groups such as critically ill patients or those undergoing surgery or invasive procedures [22]. To further clarify the mechanisms underlying the nosocomial transmission and persistence of SIHP-MRSA, we performed molecular epidemiological analyses to characterize its genotypes. Overall, SIHP-MRSA isolates in this study were predominantly represented by ST5-II-t2460 and ST59-IVa-t437 clones, each showing marked geographic associations. Independent of hemolytic phenotype, the distribution of these clones has been shown to vary by region and by patient population from which they are recovered. Prior research reported major lineage replacement within MRSA, with several emerging clones, including ST59 and ST5, becoming dominant over time [19, 23]. These clones have spread widely across healthcare settings worldwide, increasing MRSA genetic diversity [23]. Broadly, ST5-t2460-II is highly prevalent in northern China, whereas ST59-IVa-t437 is endemic in Southeast Asia and predominates in eastern and southern China [5, 19, 24, 25]. Furthermore, ST5-II-t2460 has been reported as the dominant clone among adults [22], whereas ST59-IVa-t437 is more commonly observed in pediatric populations [21, 26]. For SIHP-MRSA specifically, genotype distributions vary substantially. Xu et al. [27] reported that SIHP-MRSA isolates were predominantly ST97, whereas Zhang et al. [5] found that most SIHP-MRSA isolates belonged to ST5. In addition to these genotypes, we identified three novel genotypes, namely ST239, ST39 and ST22, broadening the known genotypic diversity of SIHP-MRSA [5, 27]. Moreover, in this study, ST5 and ST59 isolates were mainly collected from adults aged ≥ 49 years, differing from earlier reports and suggesting that older adults may be more susceptible to SIHP-MRSA infection. Regarding the molecular mechanisms underlying SIHP-MRSA evolution, only a limited number of studies have addressed this topic. One such study revealed that insertion mutations in the agrC gene can inactivate its function, diminishing hemolysis, cytotoxicity, and intracellular survival within macrophages, while enhancing adhesion and biofilm formation, thereby contributing to increased resistance to vancomycin and daptomycin [28]. Another study indicated that the agrA-I238K mutation is a key factor enabling the widespread dissemination of ST5 MRSA in Asia [7], correlating with increased biofilm formation. Notably, agrA-I238K mutants typically lose proper agr quorum-sensing function, thereby overriding inhibition of biofilm development and promoting a biofilm-dominant lifestyle. Concurrently, reduced autolysosomal activity, enhanced extracellular matrix accumulation, and upregulated expression of surface adhesion proteins collectively reinforce biofilm structure and bacterial adaptability, fostering persistent colonization and infection while complicating clinical management [7]. The three primary hemolysins secreted by S. aureus (α, β, and δ) exhibit distinct regulatory pathways but interact functionally; α-hemolysin (encoded by hla) depends on agr-mediated RNAIII activation [4]. Although agrA mutation does not directly block α-hemolysin expression, its hemolytic activity can be inhibited by β-hemolysin through sphingomyelin hydrolysis and target disruption. β-Hemolysin (encoded by hlb) is agr-independent, regulated by prophage insertion events, and shows enhanced activity at lower temperatures; besides inhibiting α-hemolysin, β-hemolysin retains intrinsic sphingomyelinase activity. δ-Hemolysin (encoded by hld) is entirely agr-dependent, as hld is embedded within the RNAIII transcript. Therefore, agrA mutations impede RNAIII synthesis and lead to δ-hemolysin deficiency, although β-hemolysin does not alter its activity [4]. Beyond agrA mutations, another factor potentially contributing to SIHP-MRSA biofilm formation enhancement is abnormal expression of hemolysin genes, particularly upregulation of hlb [4]. Given the substantial impact of agr-related mutations on MRSA virulence and transmission, strengthening genomic surveillance of relevant clones is essential for improving treatment strategies and infection control measures [7]. As a distinct MRSA subtype, reports on PT isolates remain limited. As two major toxins produced by S. aureus, PVL promotes invasion by lysing immune cells, whereas TSST induces systemic hyperinflammation through its superantigenic activity [5]. When both toxins are present, PT isolates may show strong patient-to-patient transmission potential via the respiratory tract, as 80.6% (25/31) of isolates in this study were recovered from lower respiratory tract samples. Therefore, rapid identification and real-time monitoring of this highly virulent subtype are urgently needed for susceptible patients. Additionally, a high proportion of PT isolates was detected among SIHP-MRSA isolates in this study, differing markedly from a previous report in which ST22 represented the predominant clone [29]. Notably, PT isolates analyzed in this study were composed by multiple ST types, including ST22, expanding current understanding of the genetic diversity of SIHP-MRSA clinical isolates. Of particular concern, PT isolates have been associated with increased invasive potential, causing severe infections such as deep skin infections and toxic shock syndrome [30]. Moreover, this study not only deepens our understanding of MRSA biofilm-related diversity but also provides new evidence supporting the link between clinical isolate genotypes and biofilm-forming abilities [21]. Based on these findings, active screening for SIHP-MRSA carrying PT toxins should be strongly considered in clinical settings, and the molecular mechanisms underlying their evolution and transmission warrant further investigation. SIHP-MRSA exhibited a distinct antimicrobial resistance phenotype. Its reduced susceptibility to teicoplanin and daptomycin presents new challenges for clinical management. These resistance traits may be partly explained by the agrA-I238K mutation, which disrupts agr system activity in S. aureus. This mutation can also enhance resistance to teicoplanin and daptomycin by promoting phospholipid release and cell wall thickening [7]. Additionally, the agrA-I238K mutation frequently coexists with mutations in genes such as mprF and walR/walk, each capable of further enhancing resistance to daptomycin and teicoplanin, while concurrent carriage of a Tn5801-like transposon can induce multidrug resistance. Moreover, a high proportion of agrA-dysfunctional ST5 MRSA isolates were previously shown to exhibit heterogeneous daptomycin resistance (hDAP), a phenotype linked to agr system defects and associated with more severe infections and poor clinical outcomes, including persistent bacteremia [7]. Importantly, exogenous supplementation with synthetic PSMα peptide has been reported to markedly reduce resistant subpopulations in hDAP isolates, thereby restoring daptomycin susceptibility [31]. The addition of an agr-activating autoinducing peptide can also partially repair agr system dysfunction and promote endogenous PSMα expression, thereby supporting sustained reversal of the hDAP phenotype [31]. Furthermore, the SIHP-MRSA isolates analyzed in this study exhibited significantly elevated fluoroquinolone resistance than SCHP-MRSA isolates, representing the first such report to our knowledge. ST5 SIHP-MRSA also displayed notably higher fluoroquinolone resistance than ST59 SIHP-MRSA. Nonetheless, the underlying mechanisms responsible for this phenotypic resistance remain unclear and require further investigation. Although this study provides new insights that deepen our understanding of the molecular epidemiology, clinical relevance, and potential molecular mechanisms of SIHP-MRSA, several limitations must be acknowledged. First, this research was designed as a single-center retrospective study; therefore, the actual prevalence or nosocomial transmission of SIHP-MRSA among susceptible patients may be underestimated. Second, the study did not include functional experiments to validate the actual biological effects of agrA mutation in SIHP-MRSA clinical isolates, particularly among isolates with different genotypes and varying biofilm-forming capacities and antimicrobial resistance profiles. Third, high-resolution molecular epidemiological analyses were not performed using whole-genome sequencing techniques. Because the SIHP-MRSA isolates included in the study showed substantial nonsocomial transmission potential and long-term persistence among susceptible patients, potential microevolutionary features at the genomic level within different host environments warrant further investigation. Thus, future multicenter prospective studies incorporating functional assays and genomics analysis approaches are needed to validate and extend these findings, thereby providing a stronger theoretical foundation for precise prevention and control of SIHP-MRSA infections. Conclusions This study demonstrates substantial genotypic and phenotypic diversity among clinical SIHP-MRSA isolates collected at a tertiary teaching hospital in China. ST5-II-t2460 and ST59-t437-IVa were the predominant clones, exhibiting stronger biofilm formation and higher carriage rates of key virulence genes, including pvl and tsst-1. Notably, all SIHP-MRSA belonging to ST5 and ST59 clones displayed agr dysfunction due to the agrA-I238K mutation. Moreover, SIHP-MRSA isolates generally showed reduced susceptibility to daptomycin and teicoplanin. Of particular concern, the ST5-II-t2460 clone was widely distributed among inpatients undergoing neurosurgical procedures or mechanical ventilation, and several suspected nosocomial transmission events were identified. These findings underscore the need for close monitoring in these patient groups. Supplementary Information Supplementary Material 1. Acknowledgements We thank all laboratory staff for assisting with isolates collection, identification and storage. Abbreviations Methicillin-resistant S. aureus MRSA An incomplete hemolytic phenotype in methicillin-resistant S. aureus MRSA An complete hemolytic phenotype in methicillin-resistant S. aureus PantonValentine leucocidin Oxic Shock Syndrome Toxin 1 Staphylococcal cassette chromosome mec Multilocus Sequence Type Staphylococcal protein A typing American type culture collection Clinical and Laboratory Standards Institute Polymerase chain reaction Daptomycin Teicoplanin Authors’ contributions Wanjun Chen: Data curation, Formal analysis, Investigation, Writing original draft. Roushan Liu: Data curation, Formal analysis, Investigation, Writing-original draft. Minghui Hao: Supervision, Writing-review & editing. Junrui Wang: Conceptualization, Funding acquisition, Methodology, Project administration, Resources, Writing-review &editing. Funding The author(s) declare that financial support was received for the research and/or publication of this article. This study is supported by National Natural Science Foundation of China (Grant no. 82260416), Zhiyuan talents project of Inner Mongolia Medical University (No. ZY20241209), Science and Technology Program of the Joint Fund of Scientific Research for the Public Hospitals of Inner Mongolia Academy of Medical Sciences (No. 2024GLLH0302), and Science and Technology Plan Project of Inner Mongolian Autonomous Region (No. 2025YFSH0088). Data availability The datasets generated and/or analysed during the current study are available in the Genome Sequence Archive (GSA) repository, under accession number CRA044743 (https://ngdc.cncb.ac.cn/gsa/browse/CRA044743). Declarations Ethics approval and consent to participate This study complies with the Declaration of Helsinki. The bacterial isolates used in this study were isolated from the routine biological specimens. According to the national regulation on ethical review (No. 2016–11, 12/01/2016), the requirement for the informed consent was waived by the Ethical Committee of Inner Mongolian Medical University, which belongs to the Office of Scientific Research of Inner Mongolian Medical University. Meanwhile, this study was approved by the Ethical Committee of the Inner Mongolian Medical University (Reference No. YKD202201166). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wanjun Chen and Roushan Liu contributed equally to this work. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement The datasets generated and/or analysed during the current study are available in the Genome Sequence Archive (GSA) repository, under accession number CRA044743 (https://ngdc.cncb.ac.cn/gsa/browse/CRA044743).